Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
ALPHACAINE vs FLAGYL
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
ALPHACAINE is a local anesthetic that binds to the intracellular portion of voltage-gated sodium channels, blocking sodium influx and preventing depolarization and conduction of nerve impulses.
Metronidazole, a nitroimidazole antibiotic, enters bacterial cells and is reduced to cytotoxic intermediates that damage DNA and inhibit nucleic acid synthesis, leading to cell death. It is active against anaerobic bacteria and protozoa.
Local anesthesia for dental procedures,Local anesthesia for minor surgical procedures,Epidural anesthesia (off-label),Peripheral nerve blocks (off-label)
Bacterial vaginosis,Trichomoniasis,Amebiasis,Giardiasis,Anaerobic bacterial infections (intra-abdominal, gynecologic, skin and soft tissue, bone and joint, central nervous system, lower respiratory tract, endocarditis, septicemia),Helicobacter pylori eradication (in combination with other agents),Crohn's disease (off-label),Rosacea (topical, off-label oral use is controversial),Prevention of postoperative infection following colorectal surgery
10-20 mg IM or IV every 4-6 hours as needed; maximum 80 mg/day.
Metronidazole 500 mg intravenously every 8 hours or 500 mg orally every 8 hours.
Terminal elimination half-life: 3.5-5.0 hours (prolonged in hepatic impairment; requires dose adjustment in Child-Pugh B or C).
Terminal elimination half-life: 6-8 hours in adults with normal renal function; prolonged to 7-21 hours in hepatic impairment; no significant change in renal impairment; clinically relevant for dosing interval (usually 8-hourly).
ALPHACAINE is metabolized primarily by the liver via cytochrome P450 enzymes, specifically CYP3A4 and CYP1A2, to inactive metabolites that are excreted renally.
Hepatic metabolism via oxidation and glucuronidation; major metabolites include hydroxy metabolite (active) and acid metabolite. CYP450 enzymes involved (CYP2A6, CYP2C9, CYP3A4).
Renal: ~60-70% unchanged; Hepatic metabolism: ~20-30% via CYP3A4 and CYP2C9; Fecal: <10%.
Renal: 60-80% of dose excreted unchanged in urine; biliary/fecal: 6-15% as metabolites and unchanged drug; enterohepatic circulation contributes to prolonged elimination.
~92-95% bound, primarily to albumin and alpha-1-acid glycoprotein.
Less than 20% bound to plasma proteins (primarily albumin).
Vd: 2.5-4.0 L/kg (indicates extensive tissue distribution; large Vd suggests accumulation in peripheral tissues).
Volume of distribution: 0.6-0.8 L/kg (approximately 40-60 L in adults), indicating extensive tissue penetration; exceeds total body water, consistent with distribution into all tissues including abscess cavities and CNS.
Oral: 65-80% (first-pass effect); IM: 90-100%; IV: 100%.
Oral bioavailability: 80-100% (well absorbed); IV bioavailability: 100% (by definition); Topical: Systemic absorption minimal (<2%).
GFR 30-50 m L/min: reduce dose by 25%; GFR 15-29 m L/min: reduce dose by 50%; GFR <15 m L/min: avoid use.
No dose adjustment required for mild to moderate renal impairment (GFR >10 m L/min). For severe renal impairment (GFR <10 m L/min), reduce dose to 500 mg every 12 hours.
Child-Pugh A: no adjustment; Child-Pugh B: reduce dose by 50%; Child-Pugh C: contraindicated.
Child-Pugh A: no adjustment. Child-Pugh B: reduce dose by 50% (e.g., 250 mg every 8 hours). Child-Pugh C: reduce dose to 250 mg every 12 hours.
0.5-1 mg/kg IM or IV every 4-6 hours; maximum 4 mg/kg/day.
15-50 mg/kg/day intravenously or orally divided every 8 hours, depending on infection type and severity. Maximum 4 g/day.
Initiate at 50% of adult dose; titrate cautiously due to increased sensitivity and risk of adverse effects.
Monitor renal function; same dosing as adults unless severe renal impairment (Cr Cl <10 m L/min) requires dose reduction to 500 mg every 12 hours.
There is no FDA black box warning for ALPHACAINE.
Carcinogenicity: Metronidazole has been shown to be carcinogenic in mice and rats. Chromosomal aberrations have been reported in patients with Crohn's disease and other conditions. Use should be reserved for approved indications only.
Risk of systemic toxicity if injected intravascularly,Use with caution in patients with hepatic impairment,Use with caution in patients with cardiovascular disease,May cause methemoglobinemia in rare cases,Avoid use in patients with known hypersensitivity to amide-type anesthetics
Carcinogenicity risk (see black box warning),Neurologic effects: peripheral neuropathy, seizures, encephalopathy; discontinue if abnormal neurologic signs occur,Hematologic effects: leukopenia, neutropenia; monitor CBC,Hepatic impairment: dosage adjustment recommended,Metronidazole may cause metallic taste, dark urine, and disulfiram-like reaction with alcohol,Prolonged use may result in superinfection (e.g., C. difficile diarrhea),Potential for ethylene glycol toxicity if administered with propylene glycol-containing solutions
Hypersensitivity to ALPHACAINE or any component of the formulation,Severe hepatic impairment,Severe uncontrolled hypotension,Injection into infected or inflamed areas,History of malignant hyperthermia (relative contraindication)
Hypersensitivity to metronidazole or other nitroimidazole derivatives,First trimester of pregnancy (avoid; use during later trimesters only if clearly needed),Breastfeeding (discontinue drug or bottle-feed; excreted in breast milk),History of blood dyscrasias,Concurrent use of disulfiram (psychotic reactions may occur; wait at least 2 weeks after disulfiram),Concurrent use of propylene glycol-containing IV formulations in neonates or patients with renal impairment
No clinically significant food interactions. Grapefruit juice does not affect clearance. Avoid excessive alcohol intake as it may increase risk of sedation and dizziness.
Avoid alcohol and any products containing ethanol (including certain mouthwashes, cough syrups, and fermented foods) during therapy and for at least 48 hours after last dose. No other food restrictions.
FDA Category C. First trimester: Increased risk of spontaneous abortion and congenital anomalies (neural tube defects, cardiac malformations) based on animal studies. Second and third trimesters: Potential for fetal growth restriction, preterm labor, and neurobehavioral alterations. Avoid use unless benefit outweighs risk.
Flagyl (metronidazole) crosses the placenta. In the first trimester, use is generally avoided due to theoretical risk of teratogenicity, but data from large cohort studies do not show a significant increase in major malformations (risk category B). In the second and third trimesters, no fetal harm has been demonstrated; however, use only if clearly needed. High doses associated with fetal toxicity in animals.
Excreted in human milk; M/P ratio estimated at 0.95. Peak milk concentration occurs 1-2 hours after maternal dose. Limited data suggest low risk to term infants, but caution in preterm or ill infants. American Academy of Pediatrics recommends avoiding breastfeeding within 4 hours of maternal dose.
Metronidazole is excreted into breast milk with an M/P ratio of approximately 0.9-1.5. After a single 2 g oral dose, peak milk concentration ~10-20 mcg/m L. The American Academy of Pediatrics considers it compatible with breastfeeding, but because of potential mutagenicity, avoid high doses (e.g., 2 g single dose) for 12-24 hours; resume breastfeeding after 2-3 half-lives. Lower doses (250-500 mg) are considered safe.
Increased volume of distribution and enhanced hepatic clearance (CYP3A4 induction) in pregnancy require 30-50% dose escalation. Monitor trough levels to achieve therapeutic range (5-15 mg/L). Postpartum dose should be reduced to pre-pregnancy levels within 72 hours.
No specific dose adjustment for pregnancy. However, due to increased plasma volume and renal clearance, standard doses (e.g., 500 mg IV every 6-8 hours) may require monitoring for efficacy. Oral bioavailability unchanged. Use with caution if hepatic impairment.
ALPHACAINE (liposomal bupivacaine) provides extended analgesia up to 72 hours. Do not use with bupivacaine HCl or other local anesthetics as it may disrupt liposomal formulation. Avoid bolus injection; administer by slow infiltration only. Use with caution in hepatic impairment due to decreased clearance. Maximum dose: 266 mg (20 m L of 1.3% solution) in adults.
Flagyl (metronidazole) is first-line for anaerobic infections and bacterial vaginosis. It can cause a disulfiram-like reaction with alcohol; avoid ethanol during therapy and for 48 hours after last dose. Monitor for peripheral neuropathy with prolonged use. IV formulation is highly irritating; avoid extravasation. Use with caution in hepatic impairment; dose reduction may be needed. Metallic taste is common but benign.
You will receive a long-acting local anesthetic that provides pain relief for up to 3 days after surgery.,Do not apply heat or ice packs directly over the injection site for 24 hours.,Report any signs of infection such as redness, swelling, or warmth at the injection site.,Avoid driving or operating machinery for 24 hours if you feel dizzy or drowsy.,Take over-the-counter pain relievers as directed if breakthrough pain occurs.
Do not drink alcohol or use products containing alcohol during treatment and for 48 hours after the last dose to avoid severe nausea, vomiting, and flushing.,Take with food to reduce gastrointestinal upset.,Complete the full course even if symptoms improve to prevent resistance.,May cause a metallic taste, which is temporary.,Avoid sexual intercourse or use condoms during treatment for trichomoniasis; partners may need treatment.,Notify doctor if you experience numbness, tingling, or pain in hands/feet.,For vaginal gel, avoid alcohol-containing products (e.g., douches) for 24 hours after use.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about ALPHACAINE vs FLAGYL, answered by our medical review team.
ALPHACAINE is a Local Anesthetic that works by ALPHACAINE is a local anesthetic that binds to the intracellular portion of voltage-gated sodium channels, blocking sodium influx and preventing depolarization and conduction of nerve impulses.. FLAGYL is a Nitroimidazole Antibiotic that works by Metronidazole, a nitroimidazole antibiotic, enters bacterial cells and is reduced to cytotoxic intermediates that damage DNA and inhibit nucleic acid synthesis, leading to cell death. It is active against anaerobic bacteria and protozoa.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between ALPHACAINE and FLAGYL depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of ALPHACAINE is: 10-20 mg IM or IV every 4-6 hours as needed; maximum 80 mg/day.. The standard adult dose of FLAGYL is: Metronidazole 500 mg intravenously every 8 hours or 500 mg orally every 8 hours.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between ALPHACAINE and FLAGYL in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. ALPHACAINE is classified as Category C. FDA Category C. First trimester: Increased risk of spontaneous abortion and congenital anomalies (neural tube defects, cardiac malformations) based on animal studies. Second and th. FLAGYL is classified as Category C. Flagyl (metronidazole) crosses the placenta. In the first trimester, use is generally avoided due to theoretical risk of teratogenicity, but data from large cohort studies do not s. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.